Frontiers in Immunology (Jun 2022)

Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope

  • Weili Jia,
  • Weili Jia,
  • Tianchen Zhang,
  • Tianchen Zhang,
  • Qianyun Yao,
  • Jianhui Li,
  • Jianhui Li,
  • Ye Nie,
  • Ye Nie,
  • Xinjun Lei,
  • Xinjun Lei,
  • Zhenzhen Mao,
  • Zhenzhen Mao,
  • Yanfang Wang,
  • Yanfang Wang,
  • Wen Shi,
  • Wen Shi,
  • Wenjie Song

DOI
https://doi.org/10.3389/fimmu.2022.870458
Journal volume & issue
Vol. 13

Abstract

Read online

Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of PHC depending on their location, and although available findings are controversial, they suggest that TLS have a protective role in PHC tissues and a non-protective role in paracancerous tissues. In addition, the cellular composition of TLS can also influence the outcome of PHC. As an immunity marker, TLS can act as a marker of immunotherapy to predict its effect and help to identify patients who will respond well to immunotherapy. Modulation of TLS formation through the use of chemokines/cytokines, immunotherapy, or induction of high endothelial vein to interfere with tumor growth has been studied extensively in PHC and other cancers. In addition, new tools such as genetic interventions, cellular crosstalk, preoperative radiotherapy, and advances in materials science have been shown to influence the prognosis of malignant tumors by modulating TLS production. These can also be used to develop PHC treatment.

Keywords